Veradermics Raises $256M in IPO, Ticker: MANE

[Para 1: The Lead] Veradermics Inc., a biopharmaceutical company targeting hair restoration, successfully raised $256.3 million in an IPO priced above its marketed range. The offering, priced at $17 per share, exceeded the initial $14 to $16 range, marking a significant market entry for the New Haven-based firm. [Para 2-3: Supporting details & Context] Launched in 2019, Veradermics aims to treat mild-to-moderate pattern hair loss with a non-hormonal therapy in late-stage trials. At the IPO price, the company’s market value stands at approximately $596 million. Wellington Management and Eli Lilly & Co. each expressed interest in purchasing substantial shares, indicating strong institutional backing. With eight companies planning IPOs this week, totaling at least $100 million, Veradermics’ listing is part of a robust US market activity. The offering was led by Jefferies Financial Group Inc., Leerink Partners, Citigroup Inc., and Cantor Fitzgerald, with shares trading on the New York Stock Exchange under the ticker MANE.